Pancreatic ductal adenocarcinoma (PDAC) is defined by a dense, immunosuppressive tumor microenvironment (TME) enriched with extracellular matrix components, cancer-associated fibroblasts (CAFs), and diverse immune populations. ChIP-seq analysis of resected human PDAC identified MICAL2 as a super-enhancer–associat...
Bharti Garg, E. Mose, Briana Nyugen et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely due to rapid development of resistance to standard chemotherapies such as gemcitabine. MICAL2 is a redox-dependent regulator of actin dynamics that is overexpressed in PDAC, but its role in therapeutic resistance remains poorly un...
Ponmathi Panneerpandian, Kevin Christian Montecillo Gulay, M. Macdonald et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a deadly form of pancreatic cancer with the poorest 5-year survival rate among all solid cancers. Therefore, identifying effective therapeutic strategies is crucial for treating this disease. Using a genome-wide screening approach to find novel and targetable factors in huma...
Nirakar Rajbhandari, Deepa Sheik Pran Babu, E. Mose et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.